UPDATE 1-FDA approves Epizyme's treatment for rare tissue cancer

The U.S. Food and Drug Administration has approved Epizyme Inc's treatment for a rare, slow growing type of cancer that affects soft tissue in patients aged 16 years and above, the the drug developer said on Thursday.